Test your knowledge of the April 2024 issue of AJMC with a quick quiz!
What were the biggest challenges in improving specialist alignment in accountable care organizations (ACOs)? (select multiple, all are answers)
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More